Press Release Details

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 7, 2013--

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), today announced that the company will present insights into its lead cancer metabolism and inborn errors of metabolism (IEM) programs at the 2013 American Society of Hematology (ASH) Annual Meeting, taking place December 7-10, 2013 in New Orleans.

“We are eager for the opportunity to present preclinical data on our three lead programs at this year’s ASH Annual Meeting, which gathers many of the world’s leading hematologists,” said Scott Biller, Ph.D., chief scientific officer at Agios. “ASH is the ideal platform for us to share the progress of our two lead cancer metabolism programs, which target mutated IDH1 or IDH2 enzymes for the treatment of cancer patients carrying respective mutations, including patients with hematologic malignancies such as acute myelogenous leukemia. Importantly, for the first time, we will also present insights into our lead therapeutic candidate in inborn errors of metabolism, AG-348, which has the potential to treat patients with pyruvate kinase deficiency, a form of chronic hemolytic anemia caused by mutations in the PKR enzyme.”

The schedule for Agios’ presentations is as follows:

About Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals is focused on discovering and developing novel drugs to treat cancer and inborn errors of metabolism, or IEMs, which are rare genetic metabolic diseases, through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class lead product candidates in cancer metabolism and IEMs in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit our website at www.agios.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding Agios’ expectations and beliefs about: the potential of IDH1/IDH2 and pyruvate kinase R mutations as therapeutic targets; the potential benefits of Agios’ product candidates targeting IDH1/IDH2 or pyruvate kinase R mutations, including AG-221 and AG-348; and the benefit of its strategic plans and focus. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from Agios’ current expectations and beliefs, including the risks described under the caption “Risk Factors” included in Agios’ Quarterly Report on Form 10-Q for the quarter ended June 30, 2013, and other filings that Agios may make with the Securities and Exchange Commission (SEC) in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Agios expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Source: Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc.
Media Contact:
Dan Budwick, 973-271-6085
dan@purecommunicationsinc.com
or
Investor Contact:
Glenn Goddard
investors@agios.com